Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AMGN

Piper Sandler Maintains Overweight Rating for Amgen: Here's What You Need To Know

Piper Sandler has decided to maintain its Overweight rating of Amgen (NASDAQ:AMGN) and raise its price target from $255.00 to $260.00. Shares of Amgen are trading down 5.5% over the last 24 hours, at $235.12 per share. A move to $260.00 would account for a 10.58% increase from the current…

Benzinga

Amgen's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Amgen (NASDAQ:AMGN) posted Q1 earnings of $1.48 billion, an increase from Q4 of 22.27%. Sales dropped to $6.24 billion, a 8.88% decrease between quarters.

Benzinga

Where Amgen Stands With Analysts

Within the last quarter, Amgen (NASDAQ:AMGN) has observed the following analyst ratings:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Amgen's Q1 Better Than Expected Sales, Profit Overshadowed By Tax Disclosure

Amgen Inc (NASDAQ: AMGN) has recently received a notice of deficiency from the Internal Revenue Service centered on 2013 to 2015.

Benzinga

Recap: Amgen Q1 Earnings

Amgen (NASDAQ:AMGN) reported its Q1 earnings results on Wednesday, April 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amgen beat estimated earnings by 2.41%, reporting an EPS of $4.25 versus an estimate of $4.15.

Benzinga

4 Biotech Stocks to Add to Your Watchlist

The surging demand for viable drugs and vaccines, advanced therapies, and increasing investments in research and development make the biotech industry’s prospects bright. Thus, it could be wise to invest in fundamentally sound biotech stocks Amgen (AMGN), Vertex Pharmaceuticals (VRTX), BioNTech (BNTX), and Corcept Therapeutics (CORT).

StockNews.com

Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen

Molecular Partners AG's (NASDAQ:MOLN) collaborating partner Amgen Inc (NASDAQ:AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners following a strategic pipeline review. MP0310 is a dual-targeted compound targeting both FAP and 4-1BB that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Earnings Preview: Amgen

Amgen (NASDAQ:AMGN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Amgen will report an earnings per share (EPS) of $4.15.

Benzinga

If You Invested $100 In Amgen 15 Years Ago, Here's How Much You Would Have Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 2.31% on an annualized basis producing an average annual return of 9.87%. Currently, Amgen has a market capitalization of $136.97 billion.

Benzinga

Amgen's Stelara-Based Biosimilar Shows Comparable Efficacy, Safety Profile For Psoriasis

Amgen Inc (NASDAQ:AMGN) announced preliminary results from a Phase 3 study of ABP 654 compared to Janssen Biotech Inc's Stelara (ustekinumab) in moderate to severe plaque psoriasis. The study met the primary efficacy endpoint, demonstrating no clinically meaningful differences between ABP 654 and Stelara. The primary analysis evaluated the percentage…

Benzinga

Where Amgen Stands With Analysts

Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter:

Benzinga

Amgen's Lumakras Shows Two-Year Overall Survival Of 32.5% In KRAS-Mutated Lung Cancer

Amgen Inc (NASDAQ:AMGN) announced the presentation of long-term data from the CodeBreaK 100 Phase 1/2 trial of Lumakras (sotorasib) in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). In the long-term, two-year analysis of 174 heavily pretreated patients, Lumakras demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, disease control rate (DCR) of 83.7%,…

Benzinga

$1000 Invested In Amgen 10 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.13% on an annualized basis producing an average annual return of 13.98%. Currently, Amgen has a market capitalization of $136.43 billion.

Benzinga

4 Surging Dow Jones Stocks to Add to Your Watchlist

Despite volatile market conditions currently, owing in varying degrees to the Russia-Ukraine crisis and a hawkish Fed, a continuing economic rebound is still expected by many experts. With the slight easing of investor concerns, the Dow Jones Industrial Average has witnessed a solid recovery since mid-March. So, we think it…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.42% on an annualized basis.

Benzinga

A Bullish Sign Appears On Amgen's Chart

If history is any guide, there may be good fortune ahead for shares of Amgen (NASDAQ:AMGN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

This Is What Whales Are Betting On Amgen

Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

What 10 Analyst Ratings Have To Say About Amgen

Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What Are Whales Doing With Amgen

Benzinga

Amgen's Q4 Sales Remain Flat As Its Biggest Product Flounders

Amgen Inc's (NASDAQ: AMGN) Q4 revenues incr

Benzinga

What's Going On With Amgen Stock During Today's After-Hours Session

Shares of Amgen Inc. (NASDAQ: AMGN) stepped higher following the release of its Q4 earnings report showing an EPS beat and a slight miss on sales.

Benzinga

Amgen: Q4 Earnings Insights

Amgen (NASDAQ:AMGN) reported its Q4 earnings results on Monday, February 7, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amgen beat estimated earnings by 5.83%, reporting an EPS of $4.36 versus an estimate of $4.12.

Benzinga

A Preview Of Amgen's Earnings

Amgen (NASDAQ:AMGN) is set to give its latest quarterly earnings report on Monday, 2022-02-07. Here's what investors need to know before the announcement. Analysts estimate that Amgen will likely report an Earnings Per Share (EPS) of $4.12.

StockNews.com

3 Top Dow Jones Stocks to Safeguard Your Portfolio

The market remains turbulent amid worries related to rising inflation, looming interest rate hikes, and geopolitical tensions. However, the Dow Jones Industrial Average is down the least out of the three major indices. Investing in hot Dow stock Merck (MRK), Amgen (AMGN), and Walgreens (WBA) could help safeguard your portfolio…

Benzinga

Amgen's Lumakras Approved In Japan For Pretreated Lung Cancer Patients

Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) has been approved in Japan for KRAS G12C-mutated positive, unres

1 … 3 4 5 6

Organisations

Internal Revenue Service

Vertex Pharmaceuticals Incorporated

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.